Drugs / CIL001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07472907 | Aug 2026 → Jul 2027 expected | synaptopathy | Cilcare SAS | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-25 | Cilcare SAS | Cilcare wins prestigious Hearing Technology Innovator Award for CIL001 cilcare.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIL001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07472907 ↗ |
| Known as | Paliroden | “CIL001 (Paliroden)” NCT07472907 ↗ |
| Modality | Small molecule | “CIL001 is a neurotrophic small molecule” NCT07472907 ↗ |
| Route | Other | “Single unilateral transtympanic administration” NCT07472907 ↗ |